Oncologists can now provide patients a wide array of treatment options.
Lung-MAP and the National Lung Matrix Trial aim to deliver precision-based, FDA-approved treatment to patients with lung cancer by using a streamlined trial design that allows flexibility for the investigators, patients, and drug manufacturers.
Muhammad Rizvi, MD, discusses lung cancer research from ASCO 2014.
Patients can learn more about resources that can help them quit smoking in this informational fact sheet.
This patient information sheet addresses common questions about the harms of smokeless tobacco.
This fact sheets answers common questions patients may have about the link between cigar smoking and cancer.
This patient fact sheet contains information on the different types of tumors as well as an overview of available biomarker tests and personalized medicine.
This slideshow reviews drug information for ZYKADIA™ (ceritinib), indicated for anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).
This slideshow reviews Abraxane® (paclitaxel protein-bound particles (albumin-bound) for patients with non-small cell lung cancer.
Table of Contents
Slide 3: Indication, Dosage, ...
By Sandra Cuellar, PharmD, BCOP
A 63-year-old male is referred by his primary care physician for work-up of possible lung cancer. ...
By Tara Morrison, MD; Yu-Ning Wong, MD, MSCE
A 66-year-old African American man presented with a several month history of weight ...
More people in the United States die from lung cancer than any other type of cancer. This is true for ...
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|